By Stephen Nakrosis
GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule.
Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added.
In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years.
Vaccine doses will be ready for use in the U.S. in summer, GSK said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 16, 2025 17:41 ET (21:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。